Recurrent Hyperkalemia In Renin-Angiotensin-Aldosterone System Inhibitor (Raasi) Treatment Stuck Between A Rock And A Hard Place
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY（2021）
摘要
Renin-angiotensin-aldosterone system inhibitors (RAASis) represent a cornerstone in the treatment of proteinuric CKD, supported by multiple clinical trials showing their effectiveness in delaying its progression ([1][1]). Their use has been recommended by major consensus clinical practice guidelines
更多查看译文
关键词
hyperkalemia, renin angiotensin system, cardiovascular disease key
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要